Jump to content

CYP4A22

From Wikipedia, the free encyclopedia
CYP4A22
Identifiers
AliasesCYP4A22, cytochrome P450 family 4 subfamily A member 22
External IDsOMIM: 615341; MGI: 3611747; HomoloGene: 134044; GeneCards: CYP4A22; OMA:CYP4A22 - orthologs
EC number1.14.14.80
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001010969
NM_001308102

NM_172306
NM_007821

RefSeq (protein)

NP_001010969
NP_001295031
NP_001295031.1

NP_758510

Location (UCSC)Chr 1: 47.14 – 47.15 MbChr 4: 115.27 – 115.3 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

CYP4A22 (cytochrome P450, family 4, subfamily A, polypeptide 22) also known as fatty acid omega-hydroxylase is a protein which in humans is encoded by the CYP4A22 gene.[5]

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This gene is part of a cluster of cytochrome P450 genes on chromosome 1p33.[6]

CYP4A22 was once considered, along with CYP4A11, CYP4F2, and CYP4F3, as active in metabolizing arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) by an omega oxidation reaction with the predominant 20-HETE-synthesizing enzymes in humans being CYP4F2 followed by CYP4A11; 20-HETE regulates blood flow, vascularization, blood pressure, and kidney tubule absorption of ions in rodents and possibly humans.[7] However, human CYP4A22 is expressed at very low levels in few tissues and may not be a functional enzyme in regard to the metabolism of arachidonic acid to 20-HETE.[8][9]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000162365Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000078597Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Hiratsuka M, Nozawa H, Katsumoto Y, Moteki T, Sasaki T, Konno Y, Mizugaki M (Jul 2006). "Genetic polymorphisms and haplotype structures of the CYP4A22 gene in a Japanese population". Mutation Research. 599 (1–2): 98–104. doi:10.1016/j.mrfmmm.2006.02.008. PMID 16806293.
  6. ^ Public Domain This article incorporates public domain material from "Entrez Gene: CYP4A22". Reference Sequence collection. National Center for Biotechnology Information.
  7. ^ Hoopes SL, Garcia V, Edin ML, Schwartzman ML, Zeldin DC (Jul 2015). "Vascular actions of 20-HETE". Prostaglandins & Other Lipid Mediators. 120: 9–16. doi:10.1016/j.prostaglandins.2015.03.002. PMC 4575602. PMID 25813407.
  8. ^ Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y, Cupples LA, Guo CY, Demissie S, O'Donnell CJ, Brown NJ, Waterman MR, Capdevila JH (Jan 2005). "Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension". Circulation. 111 (1): 63–9. CiteSeerX 10.1.1.335.1764. doi:10.1161/01.CIR.0000151309.82473.59. PMID 15611369.
  9. ^ Edson KZ, Rettie AE (2013). "CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities". Current Topics in Medicinal Chemistry. 13 (12): 1429–40. doi:10.2174/15680266113139990110. PMC 4245146. PMID 23688133.
[edit]

Further reading

[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.